U.S. Markets close in 20 mins.

GlaxoSmithKline plc (GSK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
40.095+0.175 (+0.438%)
As of 3:40PM EDT. Market open.
People also watch
Full screen
Previous Close39.920
Bid40.080 x 3000
Ask40.090 x 2200
Day's Range39.861 - 40.140
52 Week Range37.200 - 44.540
Avg. Volume2,712,184
Market Cap91.6B
PE Ratio (TTM)39.86
Earnings DateN/A
Dividend & Yield1.99 (4.93%)
Ex-Dividend Date2017-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?
    Zacks6 hours ago

    Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?

    GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

  • Reuters12 hours ago

    GSK's new triple lung drug beats other modern inhalers in study

    GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments. Britain's biggest drugmaker believes the results confirm the potential of the once-daily single inhaler, Trelegy Ellipta, a product it hopes will offset the impact of generic competition to the older lung drug Advair. Trelegy won approval based on clinical tests showing it improved lung function and exacerbations more than AstraZeneca's long-established two-drug inhaler Symbicort, which works in a similar way to Advair.

  • FDA OKs Glaxo's inhaler, first one to combine 3 medicines
    Associated Press23 hours ago

    FDA OKs Glaxo's inhaler, first one to combine 3 medicines

    TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis.